4/A

PRIMARY DOCUMENT

Company: Aquestive Therapeutics, Inc.
Filed: October 2, 2024
Period of Report: March 9, 2024
Accession Number: 0001214659-24-017009

View Document ↗ View on SEC.gov ↗